Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Waiting for the vaccine in Cergy, France. Photo: Martin Bureau/AFP via Getty

Use of the Oxford/AstraZeneca vaccine was halted across much of Europe today, including in France, Germany, Italy and Spain.

Why it matters: The suspensions followed reports that a small number of patients who received the vaccine experienced blood clots. But public health agencies, including the World Health Organization and the EU’s own medical arm, say there’s no indication that the blood clots were caused by the vaccine, or that the risks of giving the shot outweigh those of delaying it.

  • AstraZeneca says that out of the 17 million people who have received the vaccine in the EU and U.K., the number experiencing such symptoms is actually lower than would be expected in the general population.
  • Still, safety boards from the WHO and the European Medicines Agency (EMA) will convene on Tuesday to discuss the situation.
  • The state of play: The vaccine has been approved by the WHO and some 70 countries. Real-world data from the U.K., where the vaccine has been used most widely, suggests it's highly effective at preventing serious cases. No blood clotting concerns have been reported there.

Driving the news: Denmark and Norway were first to suspend the shot last Thursday, and the EU’s most populous countries followed suit today, with leaders describing the suspensions as precautionary.

  • French President Emmanuel Macron said distribution would be halted for 24 hours pending an EMA assessment.
  • Some experts fear such moves risk increasing vaccine hesitancy and further slowing distribution at a dangerous time, given the ongoing vaccine shortages and fast-spreading variants.
  • Indonesia cited the situation in Europe today in delaying its rollout, while Canadian Prime Minister Justin Trudeau reassured Canadians that the vaccine was safe, and leaders in the U.K. defended the homegrown jab.

The big picture: This is arguably the most important vaccine in the world in the near term. Around 3 billion doses have been reserved to date, and more than half are destined for developing countries.

  • The vaccine is relatively affordable (it’s not being sold for a profit) and easy to transport and store compared to the Pfizer and Moderna shots.
  • The COVAX initiative is sending AstraZeneca doses all over the world, often to countries that have no other source of vaccines.

Yes, but: The rollout of the vaccine in Europe has been plagued by confusion, distrust and even animosity.

  • AstraZeneca has delivered only half the doses it promised the EU, leading to anger and in one case an export ban.
  • The doses that have arrived have been administered remarkably slowly due to hesitancy among the public — fueled in part by skeptical rhetoric from politicians like Macron — and delays in granting approval for people over 65.

In the U.S., which ordered 300 million doses, the vaccine has still yet to be approved.

  • AstraZeneca’s U.S. trial was paused for seven weeks last fall. Concerns about the company's trials intensified after it emerged that some British participants had been mistakenly given a half-strength dose (surprisingly, they had better results).
  • The trial data is now at last being reviewed by independent monitors, and emergency authorization could come in about a month, National Institutes of Health Director Francis Collins told Reuters today.
  • Collins said he wasn’t concerned about the reports of blood clots, adding, “There may be a bit of an overreaction to something that is unrelated to the vaccine itself.”

For now, tens of millions of doses are sitting at a facility in Ohio, the NY Times reports.

  • The White House has rejected requests to send them abroad — including, reportedly, from the European Union.

Go deeper: Europe's new coronavirus spike is a warning to the U.S.

Go deeper

Complaint to FTC: Amazon search results full of potentially deceiving ads

Photo: Nigel Kirby/Loop Images/Universal Images Group via Getty Images

Amazon does not sufficiently distinguish between its search results and paid ads, potentially "deceiving millions of consumers," according to a complaint filed to the Federal Trade Commission.

Why it matters: Joan Moriarty, research director for the Strategic Organizing Center, a coalition of labor unions that filed the complaint, told the Washington Post the group is "very hopeful" that the FTC will investigate the complaint because Lina Khan (D), a known Amazon critic, is now chair.

3 hours ago - Health

Pfizer-BioNTech: Booster doses more effective at blocking Omicron

Prepared doses of the BioNtech-Pfizer Covid-19 coronavirus vaccine in Germany on Dec. 7. Photo: Thomas Kienzle/AFP via Getty Images

Pfizer and BioNTech said Wednesday that two doses of their COVID-19 vaccine were significantly less effective at neutralizing the Omicron variant in early lab tests, but a three-dose regimen was more effective.

Why it matters: Omicron, which has been labeled a variant of concern by the World Health Organization after being identified by scientists in South Africa last month, has forced vaccine makers to reassess the effectiveness of their vaccines against this specific new form of coronavirus.

Mike Allen, author of AM
3 hours ago - Politics & Policy

Biden unveils "Building a Better America" branding

President Biden speaks on infrastructure while visiting a bridge in Woodstock, N.H., last month. Photo: John Tully/Getty Images

President Biden today launched a new website and unveiled bold new branding as part of a nationwide tour to sell the benefits of his infrastructure package.

Why it matters: The White House says passage of the new law shows the ability to "forge bipartisan consensus and prove our democracy can deliver big wins" even in these toxic times.